Drugs / MDR-001
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07550634 | Jun → Jul 2026 overdue | liver disorder | MindRank AI Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07550621 | May 2026 overdue | — | MindRank AI Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07110766 | Aug → Sep 2025 overdue | obesity disorder | MindRank AI Ltd | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06778850 | Jun 2023 → Jul 2024 | — | MindRank AI Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06606483 | Sep 2024 → Jul 2025 overdue | obesity disorder | MindRank AI Ltd | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07274137 | Feb 2026 → Jun 2027 expected | obesity disorder | MindRank AI Ltd | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-09-29 | MindRank AI Ltd | Results MindRank Announces Positive 12-week Once-Daily（QD）Results for AI-Designed Oral GLP-1 Agonist MDR-001 in Adults with Obesity mindrank.ai ↗
MDR-001 achieved a mean body weight reduction of -8.9% compared with -0.6% in placebo group (P<0.001). |
| 2025-09-17 | MindRank AI Ltd | Results MindRank Presented Clinical Update on Oral GLP-1RA MDR-001 at LSX World Congress 2025, Highlighting AI-Powered Innovation mindrank.ai ↗
MDR-001 also showed a promising safety and tolerability profile, with no treatment-related serious adverse events (SAEs) reported and a markedly lower discontinuation rate than the 15%–50% typically observed in clinical trials of GLP-1 therapies[1,2]. |
| 2025-06-19 | MindRank AI Ltd | Results MindRank Announces Positive Phase 2b Results for AI-Designed Oral GLP-1 Receptor Agonist MDR-001 in Adults with Obesity or Overweight mindrank.ai ↗
Participants receiving MDR-001 achieved mean body weight reductions ranging from 8.2% to 10.3% (7.4-9.2 kg) compared to 2.5% (2.4 kg) in the placebo group (p<0.00001). |
| 2022-12-23 | MindRank AI Ltd | Regulatory MindRank Announces U.S. FDA Clearance of IND Application for MDR-001, a Novel GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes and Obesity mindrank.ai ↗
the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for MDR-001 |
All press releases naming this drug 8 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDR-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07274137 ↗ |
| Action | Activate | “GLP-1 receptor agonist” NCT07550621 ↗ |
| Modality | Small molecule | “small molecule MDR-001 tablets” NCT06606483 ↗ |
| Route | Oral | “Administered orally” NCT06606483 ↗ |